Overview

A Single Arm Clinical Study of Dendritic Cell Vaccine Loaded With Circular RNA Encoding Cryptic Peptide for Patients With HER2-negative Advanced Breast Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2027-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this clinical trial is to understand the safety and tolerability of CircFAM53B-219aa DC vaccine monotherapy and its combination with camrelizumab in the treatment of HER2-negative advanced breast cancer, as well as to evaluate its efficacy.

Phase:

PHASE1

Details

Lead Sponsor:

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Treatments:

camrelizumab